NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 296)
Posted On: 05/26/2021 4:24:34 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder, CEO Authors Book Focused on Groundbreaking Work
Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach is built. Vivos is focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including OSA. The company’s novel approach involves the skills of dentists who have been specially trained and the first nonsurgical, noninvasive and cost-effective treatment for people with mild-to-moderate OSA. “In many respects, this book is the culmination of my life’s work and research, starting with the theoretical foundation set forth in the Spatial Matrix Hypothesis that I first published in 2004 and continuing through the ensuing years with numerous confirmational patient studies in clinical settings,” said Vivos founder and chief medical officer Dr. G. Dave Singh in the press release. “Having the opportunity to bring this technology to the world to help patients who are suffering continues to be my mission, and the overarching goal with this book is to spread the word far and wide about how this technology can truly make a difference in how we approach thinking about and treating downstream health conditions like OSA moving forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach is built. Vivos is focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including OSA. The company’s novel approach involves the skills of dentists who have been specially trained and the first nonsurgical, noninvasive and cost-effective treatment for people with mild-to-moderate OSA. “In many respects, this book is the culmination of my life’s work and research, starting with the theoretical foundation set forth in the Spatial Matrix Hypothesis that I first published in 2004 and continuing through the ensuing years with numerous confirmational patient studies in clinical settings,” said Vivos founder and chief medical officer Dr. G. Dave Singh in the press release. “Having the opportunity to bring this technology to the world to help patients who are suffering continues to be my mission, and the overarching goal with this book is to spread the word far and wide about how this technology can truly make a difference in how we approach thinking about and treating downstream health conditions like OSA moving forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)